Company profile: Brii Biosciences
1.1 - Company Overview
Company description
- Provider of innovative medicines developed to improve public health in China, focusing on treatment options and preventive measures for Hepatitis B (prevention in Asia-Pacific excluding Japan), HIV therapies, NTM lung disease (Greater China rights), MDR/XDR Gram-negative bacterial infections (with Monash University), and anxiety and depressive disorders via internally discovered programs.
Products and services
- HIV Treatment: Develops therapeutics for HIV leveraging internally discovered programs to deliver candidate treatments for China’s public health needs (internally discovered)
- Hepatitis B Prevention: Creates preventive measures for Hepatitis B focused on the Asia-Pacific region excluding Japan to prevent infection and support regional public health (region-specific)
- Hepatitis B Treatment: Engineers treatment options by advancing novel therapeutic candidates through various stages of clinical trials for China’s public health needs (clinical-stage)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Brii Biosciences
Prodesse
HQ: United States
Website
- Description: Provider of molecular diagnostic reagents for infectious disease applications, with three FDA 510(k) cleared products in the United States and two CE-marked products in Europe; products can be used with various nucleic acid extraction and real-time PCR.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Prodesse company profile →
GeoVax
HQ: United States
Website
- Description: Provider of vaccine and cancer therapy R&D, including GEO-CM04S1, a next‑generation Covid‑19 vaccine in Phase 2 for immunocompromised patients and as a heterologous booster; Gedeptin for advanced head and neck cancer (Phase 1/2 enrollment completed); preventive vaccines for Mpox, smallpox, Ebola (Zaire/Sudan), Marburg, malaria and Zika; an MVA vaccine platform using Modified Vaccinia Ankara; and GDEPT technology for solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeoVax company profile →
Ashvattha Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage precision nanomedicines and PET imaging agents, developing D-4517.2 for wet AMD and DME, OP-801 targeting CNS macrophages/microglia as a biomarker of neuroinflammation, OP-101 to modulate inflammatory cell activity in severe COVID-19 and other inflammatory diseases, and CSF1R Dendranib, a CSF1R tyrosine kinase inhibitor for multiple sclerosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ashvattha Therapeutics company profile →
Mucosis
HQ: The Netherlands
Website
- Description: Provider of clinical-stage mucosal vaccines delivered needle-free via the nose or mouth, including SynGEM®, an intranasal vaccine candidate to prevent respiratory syncytial virus infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mucosis company profile →
BioVersys
HQ: Switzerland
Website
- Description: Provider of biopharmaceutical therapies and novel antibacterial products to combat multidrug-resistant bacterial infections, developing new mode-of-action compounds that switch off drug resistance and restore efficacy of approved antibiotics across Gram-negative, Gram-positive, and Tuberculosis pathogens, with a pipeline advancing through human clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioVersys company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Brii Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Brii Biosciences
2.2 - Growth funds investing in similar companies to Brii Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Brii Biosciences
4.2 - Public trading comparable groups for Brii Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →